Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02597634 · ClinicalTrials.gov registry record · Phase 3
Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)
A Phase 3 study of Delayed Onset Muscle Soreness (DOMS), sponsored by Strategic Science & Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
- 3
- Study locations
NCT02597634 is a Phase 3 study of Delayed Onset Muscle Soreness (DOMS) that has completed, run by Strategic Science & Technologies. The registered enrollment target is 156 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT02597634, a Phase 3 study of Delayed Onset Muscle Soreness (DOMS), has completed, sponsored by Strategic Science & Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a Phase 3, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated with DOMS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SST-0225
Study Locations (3)
Florida
- Site #203 - Hollywood
- Site #201 - South Miami
Missouri
- Site #202 - Springfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02597634
The ClinicalTrials.gov registry entry for NCT02597634 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Strategic Science & Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Delayed Onset Muscle Soreness (DOMS) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02597634 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT02597634 about?
NCT02597634 is a clinical study titled "Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)". This is a Phase 3, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated with DOMS.
What is the current status of trial NCT02597634?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2015-11. Estimated completion is 2016-10.
What conditions does trial NCT02597634 study?
This clinical trial studies the following conditions: Delayed Onset Muscle Soreness (DOMS).
What interventions are being tested in trial NCT02597634?
The interventions under investigation include: Placebo (DRUG), SST-0225 (DRUG).
Who is sponsoring clinical trial NCT02597634?
This trial is sponsored by Strategic Science & Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02597634 being conducted?
This trial has 3 study locations across Florida, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delayed Onset Muscle Soreness (DOMS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.